


RESEARCH HIGHLIGHTS



Rare clones destined to cause relapse isolated in diagnosis samples of acute lymphoblastic leukemia

A finding by a Terry Fox-funded team will allow researchers to study relapse prone cells before they progress to overt disease recurrence, opening the door for the creation of therapies that target these cells.




Clinical trial reveals more effective way to treat aggressive prostate cancers

A clinical trial led by BC-based researchers partly funded by the TFRI has revealed that administering abiraterone acetate before enzalutamide delayed cancer progression by an average of four months.



MRI images predict what patients with brain metastasis will respond to radiotherapy

Using machine learning techniques to analyze conventional magnetic resonance imaging (MRI) could help predict outcomes for brain metastasis patients treated with stereotactic radiation therapy, according to a new study by TFRI-funded researchers.



Antigens found in non-coding ovarian cancer DNA may provide clues for therapeutic vaccines

Researchers in Montreal are hoping that tumour specific antigens found in the non-coding regions of DNA might be used to create vaccines for patients with an aggressive form of ovarian cancer.



New T-cell finding identifies pancreatic cancer patients with hallmarks of antitumour response

A Pan-Canadian team has found that a small subset of patients with pancreatic cancer exhibit a T-cell inflamed profile. This could open the door for the potential use of immunotherapies to treat patients diagnosed with this deadly disease.

TFRI NEWS

New study reveals genetic “scars” caused by cancer therapy

TFRI Update on COVID-19 and cancer research funding

Links is compiled and circulated quarterly by TFRI to highlight recently published research by our funded investigators. It is produced by TFRI HQ in Vancouver, BC. TFRI is either the principal or supporting funder of the research presented here. We hope you enjoyed reading this issue. Please send any questions or feedback to: links@tfri.ca

Previous issues are available online in our [E-Newsletter Archive](#).

Visit www.tfri.ca to learn more about our research investment portfolio

TFRI is either the principal or supporting funder of the research presented here. Funded investigators are invited to submit their publications to us for consideration in an upcoming issue.